TrialCancer2014

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.

Karen L Reckamp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.